Mosby's 2014 Nursing Drug Reference (93 page)

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

cilostazol (Rx)

(sih-los′tah-zol)

Pletal

Func. class.:
Platelet aggregation inhibitor

Chem. class.:
Quinolinone derivative

Do not confuse:
Pletal
/Plendil

ACTION:

Reversibly inhibits cellular phosphodiesterase; inhibits platelet aggregation induced by thrombin, ADP, collagen, arachidonic acid, EPINEPHrine, stress

USES:

Intermittent claudication

Unlabeled uses:
Buerger’s disease, percutaneous coronary intervention (PCI)

CONTRAINDICATIONS:

Hypersensitivity, acute MI, active bleeding conditions, hemostatic conditions

 

Black Box Warning:

CHF

Precautions:
Pregnancy (C), breastfeeding, children, geriatric patients, previous hepatic disease, cardiac/renal disease, increased bleeding risk, low platelet count, platelet dysfunction

DOSAGE AND ROUTES
Calculator

• Adult:
PO
100 mg bid taken ≥30 min before or 2 hr after breakfast and dinner or 50 mg bid if using products that inhibit CYP3A4 and CYP2C19; 12 wk of treatment may be needed for beneficial effect

PCI to prevent acute coronary thrombosis/Buerger’s disease (unlabeled)

• Adult:
PO
100 mg bid

Available forms:
Tabs 50, 100 mg

Administer:

• 
Give bid 30 min before or 2 hr after meals; do not give with grapefruit juice

SIDE EFFECTS

CNS:
Dizziness
, headache

CV:
Palpitations, tachycardia
, nodal dysrhythmia, postural hypotension

EENT:
Blindness, diplopia, ear pain, tinnitus, retinal hemorrhage

GI:
Nausea
, vomiting,
diarrhea
, GI discomfort, colitis, cholelithiasis, ulcer, esophagitis, gastritis, anorexia,
flatulence, dyspepsia

GU:
Cystitis, frequency, vaginitis,
vaginal hemorrhage,
hematuria

HEMA:
Bleeding (epistaxis, hematuria, retinal hemorrhage, GI bleeding), thrombocytopenia,
anemia,
polycythemia, aplastic anemia

INTEG:
Rash
, urticaria, dry skin,
Stevens-Johnson syndrome

MISC:
Back pain, headache, infection, myalgia, peripheral edema
, chills, fever, malaise, diabetes mellitus

RESP:
Cough, pharyngitis, rhinitis
, asthma, pneumonia

PHARMACOKINETICS

95%-98% protein binding; metabolism: hepatic extensively by CYP3A4, 2C19 enzymes; excreted in urine (74%), feces (20%); half-life 11-13 hr

INTERACTIONS

Increase:
bleeding tendencies—anticoagulants, NSAIDs, thrombolytics, abciximab, eptifibatide, tirofiban, ticlopidine

Increase:
cilostazol levels—CYP3A4, CYP2C19 inhibitors; diltiazem, erythromycin, clarithromycin, verapamil, protease inhibitors, omeprazole; exercise caution when coadministering with fluvoxaMINE, FLUoxetine, ketoconazole, isoniazid, gemfibrozil, omeprazole, itraconazole, voriconazole, fluconazole; reduce dose to 50 mg bid

Decrease:
cilostazol levels—CYP3A4 inducers

Drug/Herb

Decrease:
action—chamomile, coenzyme Q10, flax, goldenseal, St. John’s wort

Drug/Food

• 
Do not use with grapefruit juice, toxicity may occur

NURSING CONSIDERATIONS
Assess:

 

Black Box Warning

For underlying CV disease because CV risk is great; for CV lesions with repeated oral administration; do not administer to patients with CHF of any severity; for severe headache, signs of toxicity

• 
Blood studies: CBC q2wk, Hct, Hgb, PT

Evaluate:

• 
Therapeutic response: improved walking distance, duration; decreased pain

Teach patient/family:

• 
To avoid hazardous activities until effect is known

• 
To report any unusual bleeding

• 
To report side effects such as diarrhea, skin rashes, subcutaneous bleeding

• 
That effects may take 2-4 wk; treatment of up to 12 wk may be required for necessary effect

• 
That reading the patient package insert is necessary

• 
That it is best to discontinue tobacco use, not to use grapefruit juice

• 
That there are many drug and herb interactions; obtain approval from prescriber before use

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

cimetidine (
OTC
, Rx)

(sye-met′i-deen)

Acid Reducer, Equaline Acid Reducer, Good Sense Heartburn Relief, Nu-Cimet
, Tagamet, Tagamet HB

Func. class.:
H
2
-histamine receptor antagonist

Chem. class.:
Imidazole derivative

ACTION:

Inhibits histamine at H
2
-receptor site in the gastric parietal cells, which inhibits gastric acid secretion

USES:

Short-term treatment of duodenal and gastric ulcers and maintenance; management of GERD (PO) and Zollinger-Ellison syndrome; prevention of upper GI bleeding; prevent, relieve heartburn, acid indigestion, upper GI bleeding

Unlabeled uses:
Prevention of aspiration pneumonitis, stress ulcers, angioedema, molluscum contagiosum, NSAID-induced ulcer prophylaxis, verruca vulgaris

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Pregnancy (B), breastfeeding, children <16 yr, geriatric patients, organic brain syndrome, renal/hepatic disease

DOSAGE AND ROUTES
Calculator
Short-term treatment of active ulcers

• Adult/adolescents ≥16 yr:
PO
300 mg qid with meals, at bedtime × 8 wk or 400 mg bid, 800 mg at bedtime; after 8
wk, give bedtime dose only;
IV BOL
300 mg/20 ml 0.9% NaCl over 1-2 min q6hr;
IV INF
300 mg/50 ml D
5
W over 15-20 min;
IM
300 mg q6hr, max 2400 mg/day

• Child:
PO
20-40 mg/kg/day;
IM/IV
5-10 mg/kg q6-8hr

Prophylaxis of duodenal ulcer

• Adult and child >16 yr:
400 mg at bedtime or 300 mg bid

GERD

• Adult:
PO
800-1600 mg/day in divided doses × up to 12 wk

Hypersecretory conditions (Zollinger-Ellison syndrome)

• Adult:
PO/IM/IV
300-600 mg q6hr; may increase to 12 g/day if needed; OTC use ≤200 mg daily or bid, max 2×/wk

Upper GI bleeding prophylaxis

• Adult:
IV
50 mg/hr; lowered in renal disease

Heartburn

• Adult/child ≥12 yrs:
PO
200 mg Tagamet Hb up to BID, may use before eating, max 400 mg/day, max daily use up to 2 wk

Renal disease

• Adult:
PO/IV
CCr <30 ml/min, 300 mg q12hr

Verruca vulgaris (unlabeled)

• Child:
PO
30-40 mg/kg/day × 2 mo

Available forms:
Tabs 100, 200, 300, 400, 800 mg; liq 200, 300 mg/5 ml; inj 300 mg/2 ml, 300 mg/50 ml 0.9% NaCl

Administer:
PO route

• 
With meals for prolonged product effect; antacids 1 hr before or 1 hr after cimetidine

IM route

• 
May give undiluted

• 
Give at end of dialysis

• 
Inject deeply in large muscle mass, aspirate

IV route

• 
After
diluting
300 mg/20 ml of 0.9% NaCl for inj; give by
direct IV over
≥5 min;
Intermittent IV INF
may be
diluted
300 mg/50 ml of D
5
W;
run
≥30 min; or total daily dose (900 mg) diluted in 100-1000 ml D
5
W given over 24 hr
Continuous IV INF

• 
Storage of diluted sol at room temp up to 48 hr

Y-site compatibilities:
Acyclovir, alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid complex/liposome, anakinra, anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, cephapirin, chlorproMAZINE, cisatracurium, CISplatin, cladribine, clarithromycin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, doxapram, DOXOrubicin, DOXOrubicin liposome, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, folic acid, foscarnet, gallium, gatifloxacin, gemcitabine, gentamicin, gycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, meropenem, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactum, multiple vitamin injection, mycopheno
late, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, PEMEtrexed, penicillin G sodium/potassium, pentamidine, pentazocine, phenylephrine, phytonadione, pipercillin, piperacillin/tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, Ringers’ ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, topotecan, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid

SIDE EFFECTS

CNS:
Confusion, headache
, depression, dizziness, anxiety, weakness, psychosis, tremors,
seizures

CV:
Bradycardia, tachycardia,
dysrhythmias

GI:
Diarrhea
, abdominal cramps,
paralytic ileus, jaundice

GU:
Gynecomastia, galactorrhea, impotence, increase in BUN, creatinine

HEMA:
Agranulocytosis, thrombocytopenia, neutropenia, aplastic anemia, increase in PT

INTEG:
Urticaria, rash, alopecia, sweating, flushing,
exfoliative dermatitis

RESP:
Pneumonia

PHARMACOKINETICS

Half-life 1½-2 hr; 30%-40% metabolized by liver, excreted in urine (unchanged), crosses placenta, enters breast milk

PO:
Onset 30 min, peak 45-90 min; duration 4-5 hr, well absorbed

IM/IV:
Onset 10 min, peak 1/2 hr, duration 4-5 hr, well absorbed (IM)

INTERACTIONS

Increase:
toxicity due to CYP450 pathway—benzodiazepines, β-blockers, calcium channel blockers, carBAMazepine, chloroquine, lidocaine, metroNIDAZOLE, moricizine, phenytoin, quiNIDine, quiNINE, sulfonylureas, theophylline, tricyclics, valproic acid, warfarin

Increase:
bone marrow suppression-carmustine

Decrease:
absorption of cimetidine—antacids, sucralfate

Decrease:
absorption—ketoconazole, itraconazole

Drug/Lab Test

Increase:
alk phos, AST, creatinine, prolactin

False positive:
gastroccult, hemoccult tests

False negative:
TB skin tests

NURSING CONSIDERATIONS
Assess:

• 
Ulcer symptoms:
epigastric pain, duration, intensity; aggravating, ameliorating factors

Evaluate:

• 
Therapeutic response: decreased pain in abdomen; healing of ulcers; absence of gastroesophageal reflux, gastric pH of 5

Teach patient/family:

• 
That gynecomastia, impotence may occur, are reversible

• 
To avoid driving, other hazardous activities until stabilized on this medication; drowsiness or dizziness may occur

• 
To avoid OTC preparations: aspirin; cough, cold preparations; condition may worsen

• 
That smoking decreases effectiveness of product

• 
That product must be taken exactly as prescribed and continued for prescribed time to be effective; not to double dose

• 
To report bruising, fatigue, malaise; blood dyscrasias may occur

• 
To report diarrhea, black tarry stools, sore throat, rash to prescriber

Other books

The Third Sin by Aline Templeton
Conduit by Angie Martin
Eraser Lilac by Keith, Megan
To Catch a Bad Guy by Astor, Marie
Xan's Feisty Mate by Elle Boon
To Tempt A Viking by Michelle Willingham
A Glass of Blessings by Barbara Pym
Ridge by Em Petrova